# EDGAR Filing Document

**Accession Number:** 0002112339
**File Stem:** 0001193125-26-064025
**Filing Date:** 2026-2
**Character Count:** 10134
**Document Hash:** f75dfbcf7eb9b17eee3d162bd1c3e9e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-064025.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001193125-26-064025

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260211

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Savage Brian
- **CENTRAL INDEX KEY:** 0002112339

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16174
- **FILM NUMBER:** 26665392

**MAIL ADDRESS:**
- **STREET 1:** 400 INTERPACE PARKWAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TEVA PHARMACEUTICAL INDUSTRIES LTD
- **CENTRAL INDEX KEY:** 0000818686
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- **STREET 2:** 124 DVORA HANEVI'A ST.
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972 (3) 914-8213

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- **STREET 2:** 124 DVORA HANEVI'A ST.
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

## Ex-24

**<u>POWER OF ATTORNEY<br>FOR SECTION 16 REPORTING OBLIGATIONS</u>**

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Dov Bergwerk, Shira Aran-Porat and Matan Kimchi signing singly, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

(1)prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Teva Pharmaceutical Industries Limited, a company incorporated under the law of Israel, or any successor thereto (the "<u>Company</u>"), with the U.S. Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "<u>Exchange Act</u>");

(2)seek or obtain, as the undersigned's representative and on the undersigned's behalf, information of transactions in the Company's securities from any third-party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

(3)perform any and all other acts which in the discretion of such attorney-in-fact is necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

(4)this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information;

(5)any documents prepared, executed, acknowledged and/or delivered by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

(6)neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

(7)this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12<sup>th</sup> day of February, 2026.

By: /s/ Brian P. Savage

Name: Brian P. Savage

Title: Interim Chief Legal Officer

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Savage Brian<br><sub>(Last) (First) (Middle)</sub><br>C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.<br>124 DVORA HANEVI'A STREET<br><sub>(Street)</sub><br>TEL AVIV, L3 6944020<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-11 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Interim Chief Legal Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 739 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options (right to buy) | <sup>(2)</sup> | 2026-03-17 | Ordinary Shares<sup>(1)</sup> | 2253 | $53.5 | D |  |
| Stock Options (right to buy) | <sup>(3)</sup> | 2027-03-03 | Ordinary Shares<sup>(1)</sup> | 4503 | $34.7 | D |  |
| Restricted Share Units | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary Shares<sup>(1)</sup> | 18967 | <sup>(5)</sup> | D |  |
| Restricted Share Units | <sup>(6)</sup> | <sup>(6)</sup> | Ordinary Shares<sup>(1)</sup> | 13844 | <sup>(5)</sup> | D |  |
| Restricted Share Units | <sup>(7)</sup> | <sup>(7)</sup> | Ordinary Shares<sup>(1)</sup> | 15066 | <sup>(5)</sup> | D |  |
| Restricted Share Units | <sup>(8)</sup> | <sup>(8)</sup> | Ordinary Shares<sup>(1)</sup> | 14320 | <sup>(5)</sup> | D |  |

---

### Footnotes:

(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

(2) Stock options were granted on March 17, 2016, with 563 vested on each of March 17, 2017, March 17, 2018 and March 17, 2019, and 564 vested on March 17, 2020.

(3) Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.

(4) Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vesting on March 4, 2026.

(5) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

(6) Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024 and March 3, 2025, and 3,461 vesting on each of March 3, 2026 and March 3, 2027.

(7) Restricted share units were granted on March 4, 2024, with 3,766 vested on March 4, 2025, 3,766 vesting on each of March 4, 2026 and March 4, 2027, and 3,768 vesting on March 4, 2028.

(8) Restricted share units were granted on March 5, 2025, with 3,580 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.

**Signature:** /s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage  
**Date:** 2026-02-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**